Featured Editorial

  1. Some Truths You Can't Avoid About eCOA 8/13/2024

    The advantages of eCOA systems often overshadow some of the potential challenges they could create. Robert Goldman expounds on some of his first-hand experiences over the years with ePRO and eCOA implementations that went awry.

  2. What Sites Need: Trial Technology Selection, Buy-In, And Implementation 8/13/2024

    SCRS Vice President of Site Engagement Jimmy Bechtel poses questions and offers helpful tips aimed at helping sponsors understand site technology needs in this two-part series, with part one focused on technology selection and implementation.

  3. Managing Risk In New And Emerging Trial Technology Trends 7/31/2024

    As technology advances, the risk that comes with integrating them into clinical trials rises. Beazley U.S. Life Sciences Underwriter Brendan Tarte discusses how to manage risk with tech like wearables, DHTs, AI/ML, and more.

  4. Correct But Misleading: AI Hallucinations In Complex Decision-Making 7/11/2024

    Managing risks associated with AI hallucinations requires "explainability," a process that identifies patterns or behaviors in AI models that are inconsistent with training data or logical expectations. Regulators are mandating transparency in AI models used for drug testing and development.

  5. Could GenAI Dramatically Reduce The Cost Of Regulatory Medical Writing? 7/3/2024

    Time-poor regulatory professionals stand to benefit substantially from generative AI, which can speed up the creation of marketing authorization applications or life cycle maintenance activities, for example. However, success will depend on how the technology is applied and controlled.

  6. Takeda Chooses Wearable To Improve Patient Experience & Data In Sleep Study 6/27/2024

    Takeda Head of the Orexin Franchise Development and Neuroscience Portfolio Strategy Elena Koundourakis explains why her team decided to pursue the use of DHTs and the benefits of doing so, for both the patients and the data accuracy. 

  7. What Drives eConsent Adoption? Reasons May Be Different Than You Think 6/13/2024

    Increasing efficiency and reducing cost are significant drivers for adopting eConsent platforms. But are they really the factors holding back widespread adoption? Gatewood Global Principal Jeanie Magdalena Gatewood reveals other drivers in her independent research.

  8. Unlocking Next Generation Clinical Trials Through Data Sharing & Tech-Driven Approaches 5/21/2024

    New findings from a survey conducted in the U.S. indicate a significant number of trial participants are eager to have their data used by researchers. How can biopharma companies harness this?

  9. Meaningful Industry Change Means Balancing Tech And Human Touch 5/6/2024

    Technology and AI/ML are advancing at an unprecedented pace, and we must not lose sight of our industry's core: human-to-human interaction.

  10. What Can Digital Patient Twins Do For Clinical Research? 4/29/2024

    Digital patient twins have the potential to vastly improve our current healthcare systems by offering personalized therapeutics, enhanced health monitoring, and streamlined pharmaceutical manufacturing, including clinical trials.